Jeffrey M Skolnik
Overview
Explore the profile of Jeffrey M Skolnik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morrow M, Gillespie E, Sylvester A, Amin M, Belafsky P, Best S, et al.
Nat Commun
. 2025 Feb;
16(1):1518.
PMID: 39939590
Recurrent respiratory papillomatosis (RRP) is a chronic airway disease caused by Human Papillomavirus (HPV). INO-3107, DNA immunotherapy designed to elicit T-cells against HPV-6 and HPV-11, was evaluated in a 52-week...
2.
Skolnik J, Morrow M
Mol Aspects Med
. 2023 Nov;
94:101224.
PMID: 37931422
Human papillomavirus (HPV) infection represents a significant global health concern owing to its role in the etiology of conditions ranging from benign low-grade lesions to cancers of the cervix, head...
3.
Mau T, Amin M, Belafsky P, Best S, Friedman A, Klein A, et al.
Laryngoscope
. 2023 May;
133(11):3087-3093.
PMID: 37204106
Objective: To evaluate the safety, immunogenicity, and efficacy of INO-3107, a DNA immunotherapy designed to elicit targeted T-cell responses against human papillomavirus (HPV) types 6 and 11, in adult patients...
4.
Vonderheide R, Kraynyak K, Shields A, McRee A, Johnson J, Sun W, et al.
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34230114
Background: Human telomerase reverse transcriptase (hTERT) is frequently classified as a 'universal' tumor associated antigen due to its expression in a vast number of cancers. We evaluated plasmid DNA-encoded hTERT...
5.
Shore N, Morrow M, McMullan T, Kraynyak K, Sylvester A, Bhatt K, et al.
Mol Ther
. 2020 Mar;
28(5):1238-1250.
PMID: 32208168
The management of men with prostate cancer (PCa) with biochemical recurrence following local definitive therapy remains controversial. Early use of androgen deprivation therapy (ADT) leads to significant side effects. Developing...
6.
Aggarwal C, Cohen R, Morrow M, Kraynyak K, Sylvester A, Cheung J, et al.
Vaccines (Basel)
. 2020 Feb;
8(1).
PMID: 32013270
Methods: Testing of INO-3016 in animal models confirmed immunogenicity of the DNA-based therapy. A single-site open-label Phase 1 study was initiated for patients with HPV6-positive RRP. Patients were dosed with...
7.
Colosia A, Khan S, Hackshaw M, Oglesby A, Kaye J, Skolnik J
Sarcoma
. 2016 Aug;
2016:3597609.
PMID: 27516726
This systematic literature review describes adverse events (AEs) among patients with soft tissue sarcoma (STS) who received second-line or later anticancer therapies. Searches were conducted in PubMed, EMBASE, and Cochrane...
8.
Flinn I, Bartlett N, Blum K, Ardeshna K, LaCasce A, Flowers C, et al.
Eur J Cancer
. 2015 Dec;
54:11-17.
PMID: 26707592
Purpose: To assess the safety and efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Experimental Design: Relapsed or refractory DLBCL patients originally received the...
9.
Tolcher A, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara D, et al.
Clin Cancer Res
. 2014 Dec;
21(4):739-48.
PMID: 25516890
Purpose: KRAS is the most commonly mutated oncogene in human tumors. KRAS-mutant cells may exhibit resistance to the allosteric MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) and allosteric AKT inhibitors (such as...
10.
Barrett J, Patel D, Dombrowsky E, Bajaj G, Skolnik J
AAPS J
. 2013 Apr;
15(3):775-86.
PMID: 23595361
This investigation evaluated the impact of potential drug interactions on the incidence of reported toxicities seen with common dosing patterns in children with cancer, with the intent of being able...